Evidence-Based Lenalidomide Dosing Schedules

Standard Dosing Regimens

The National Comprehensive Cancer Network (NCCN) recommends lenalidomide 10mg daily for 21 out of 28 days or 28 days monthly for lower-risk MDS patients with del(5q) abnormality, with a validated response rate in multiple phase II and phase III trials 1, 2, 3
The European LeukemiaNet guidelines support either 10mg daily for 21 days every 28-day cycle or continuous daily dosing for MDS patients with del(5q) abnormality 4, 5
Lenalidomide 10mg daily dosing achieves 67% transfusion independence rates, 50% cytogenetic response rates, and a median time to response of 4.6 weeks in MDS patients with del(5q) abnormality 4
Response assessment should occur at 2-4 months in MDS patients with del(5q) abnormality receiving lenalidomide 1, 2

The NCCN recommends using dose reduction to 5mg daily rather than extending the interval between doses to manage cytopenias in MDS patients with del(5q) abnormality 4
Dose reduction to 5mg daily still achieves 42.6% transfusion independence in MDS patients with del(5q) abnormality 4
Growth factors (G-CSF) can be added to manage neutropenia while maintaining standard lenalidomide dosing in MDS patients with del(5q) abnormality 1, 2
Lenalidomide should be avoided entirely if ANC <500 cells/mcL or platelets <25,000 cells/mcL in MDS patients with del(5q) abnormality 1

Baseline liver function tests, then monitoring within 1-2 months and every 3-4 months thereafter is recommended for MDS patients with del(5q) abnormality receiving lenalidomide 6
Complete blood counts weekly for the first 8 weeks, then at least monthly is recommended for MDS patients with del(5q) abnormality receiving lenalidomide 4
Dose modifications should be based on ANC and platelet counts, not arbitrary schedule changes in MDS patients with del(5q) abnormality receiving lenalidomide 2, 3